<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(4)</volume><submitter>Ferrari A</submitter><funding>Italian Ministry of Health</funding><pubmed_abstract>Adenocarcinoma of the esophagus (EAC) and gastroesophageal junction (GEJ-AC) is associated with poor prognosis, treatment resistance and limited systemic therapeutic options. To deeply understand the genomic landscape of this cancer type, and potentially identify a therapeutic target in a neoadjuvant chemotherapy non-responder 48-year-old man, we adopted a multi-omic approach. We simultaneously evaluated gene rearrangements, mutations, copy number status, microsatellite instability and tumor mutation burden. The patient displayed pathogenic mutations of the &lt;i>TP53&lt;/i> and &lt;i>ATM&lt;/i> genes and variants of uncertain significance of three kinases genes (&lt;i>ERBB3&lt;/i>, &lt;i>CSNK1A1&lt;/i> and &lt;i>RPS6KB2&lt;/i>), along with &lt;i>FGFR2&lt;/i> and &lt;i>KRAS&lt;/i> high copy number amplification. Interestingly, tra</pubmed_abstract><journal>Genes</journal><pagination>918</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10137952</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Detection of a Novel &lt;i>MSI2-C17orf64&lt;/i> Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report.</pubmed_title><pmcid>PMC10137952</pmcid><pubmed_authors>Domizio C</pubmed_authors><pubmed_authors>Mattioli S</pubmed_authors><pubmed_authors>Ferrari A</pubmed_authors><pubmed_authors>Angeli D</pubmed_authors><pubmed_authors>Martinelli G</pubmed_authors><pubmed_authors>Domenico Raulli G</pubmed_authors><pubmed_authors>Bonora E</pubmed_authors><pubmed_authors>Fiocca R</pubmed_authors><pubmed_authors>Fonzi E</pubmed_authors><pubmed_authors>Molinari C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Detection of a Novel &lt;i>MSI2-C17orf64&lt;/i> Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report.</name><description>Adenocarcinoma of the esophagus (EAC) and gastroesophageal junction (GEJ-AC) is associated with poor prognosis, treatment resistance and limited systemic therapeutic options. To deeply understand the genomic landscape of this cancer type, and potentially identify a therapeutic target in a neoadjuvant chemotherapy non-responder 48-year-old man, we adopted a multi-omic approach. We simultaneously evaluated gene rearrangements, mutations, copy number status, microsatellite instability and tumor mutation burden. The patient displayed pathogenic mutations of the &lt;i>TP53&lt;/i> and &lt;i>ATM&lt;/i> genes and variants of uncertain significance of three kinases genes (&lt;i>ERBB3&lt;/i>, &lt;i>CSNK1A1&lt;/i> and &lt;i>RPS6KB2&lt;/i>), along with &lt;i>FGFR2&lt;/i> and &lt;i>KRAS&lt;/i> high copy number amplification. Interestingly, tra</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2026-04-07T21:01:01.568Z</modification><creation>2025-04-06T08:41:24.982Z</creation></dates><accession>S-EPMC10137952</accession><cross_references><pubmed>37107676</pubmed><doi>10.3390/genes14040918</doi></cross_references></HashMap>